VBL Therapeutics Overview
VBL has developed its Monocyte Targeting Technology (MTT), as an investigational new and specific way to limit chronic inflammation. Its program is based on the discovery of a novel target protein that is selectively expressed on the surface of monocytes and controls their ability to migrate (or 'walk' to) inflamed tissues. This protein is called MOSPD2 (the "mono-walk" receptor). The company's lead MTT candidate, VB-601, is an investigational proprietary monoclonal antibody that binds the MOSPD2 ("mono-walk") receptor and is engineered to specifically block the ability of monocytes to reach inflamed tissues. VB-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents, most of which target pro-inflammatory molecules and work through T and B lymphocytes but are not targeted to the monocyte cells. Based on pre-clinical and human ex-vivo data, VB-601 has potential utility in a wide range of immune-inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, psoriatic arthritis, non-alcoholic steatohepatitis (NASH), inflammatory bowel disease and other immune-inflammatory diseases.
Cumulative Funding Raised Over Time ($)
$16.9MDec 2021
$57.0MOct 2010
Latest News
growth-positive
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
VBL Therapeutics has filed an S-4 registration statement for a proposed merger with Notable Labs. The company expects to close the merger in Q3 2023, subject to SEC review and shareholder approvals. The merger aims to develop a pipeline of clinical-stage precision medicines for oncology using Notables Predictive Precision Medicines Platform. VBL also reported its financial results for Q1 2023, with a net loss of $2.6 million. The company recently sold its manufacturing facility in Israel for $7.1 million. VBL Therapeutics is a biopharmaceutical company focused on developing targeted therapies for immune-inflammatory diseases and cancer.
Acquisition
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
growth-positive
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
Aleph Farms, an Israeli company that grows cultivated steaks from non-modified cow cells, has acquired a manufacturing facility in Modi’in, Israel, from biotechnology company VBL Therapeutics. Aleph Farms has also signed a Memorandum of Understanding (MOU) with ESCO Aster, a Singapore-based contract manufacturing organization, to produce cultivated meat in Singapore. This move is expected to increase Aleph Farms’ production capabilities and global impact as the company approaches commercialization. The company is working closely with regulatory agencies worldwide as it prepares for the commercial launch of its first product, a cultivated thin-cut steak.
AcquisitionExpandPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $109.77M |
| Last funding | $2.82M |
| Stage | Public |
| Rounds | 5 |
| Investors | 8 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | www.vblrx.com |
Locations
HaSatat St 8, Modi'in-Maccabim-Re'ut, Israel
Photos & Videos
1 item(s)
VBL Therapeutics Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsGenesTags (10)
biotechnologyinflammatory-diseasesdrug-discoverybiopharmaceuticaloncologycancer-therapypharma-companiescancertreatmentsbioconvergenceGeographic Markets
IsraelUnited StatesVBL Therapeutics Financials
$109.77M
Total funding
Undisclosed
Capital raised
$2.82M
Last funding
Public
Funding stage
5
Total rounds
8
Investors
Cumulative Funding Raised Over Time ($)
$16.9MDec 2021
$57.0MOct 2010
Private Equity Funding
PIPE
Dec 2021
$16.95M
EIC Accelerator
Undisclosed Round
Oct 2010
$40M
GlenRock Group, Teva Pharmaceuticals' RISE Challenge, Merck Global Health Innovation Fund, Pitango VC, Max Herzberg, Kadima High Tech, Aurum Ventures M.K.I
Non-Equity Funding
GrantEvent
Dec 2021
$2.82M
EIC Accelerator Programme
Public Offering / Exit
MNAEvent
Feb 2023
Undisclosed
POEvent
May 2020
Undisclosed
POEvent
Oct 2014
Undisclosed
VBL Therapeutics Lifecycle
Cumulative Funding Raised Over Time
$16.9MDec 2021
$57.0MOct 2010
All Events
PIPE
Dec 2021
$16.95M
EIC Accelerator
Undisclosed Round
Oct 2010
$40M
GlenRock Group, Teva Pharmaceuticals' RISE Challenge, Merck Global Health Innovation Fund, Pitango VC, Max Herzberg, Kadima High Tech, Aurum Ventures M.K.I
GrantEvent
Dec 2021
$2.82M
EIC Accelerator Programme
MNAEvent
Feb 2023
Undisclosed
POEvent
May 2020
Undisclosed
POEvent
Oct 2014
Undisclosed
VBL Therapeutics News
36 articles
growth-positive
VBL Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
VBL Therapeutics has filed an S-4 registration statement for a proposed merger with Notable Labs. The company expects to close the merger in Q3 2023, subject to SEC review and shareholder approvals. The merger aims to develop a pipeline of clinical-stage precision medicines for oncology using Notables Predictive Precision Medicines Platform. VBL also reported its financial results for Q1 2023, with a net loss of $2.6 million. The company recently sold its manufacturing facility in Israel for $7.1 million. VBL Therapeutics is a biopharmaceutical company focused on developing targeted therapies for immune-inflammatory diseases and cancer.
Acquisition
Vascular Biogenics Full Year 2022 Earnings: US$0.42 loss per share (vs US$0.45 loss in FY 2021)
VBL Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
growth-positive
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
Aleph Farms, an Israeli company that grows cultivated steaks from non-modified cow cells, has acquired a manufacturing facility in Modi’in, Israel, from biotechnology company VBL Therapeutics. Aleph Farms has also signed a Memorandum of Understanding (MOU) with ESCO Aster, a Singapore-based contract manufacturing organization, to produce cultivated meat in Singapore. This move is expected to increase Aleph Farms’ production capabilities and global impact as the company approaches commercialization. The company is working closely with regulatory agencies worldwide as it prepares for the commercial launch of its first product, a cultivated thin-cut steak.
AcquisitionExpandPartners
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement
VBL Therapeutics Announces Agreement to Sell Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash
13 Best Biotech Penny Stocks To Buy Now
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
growth-negative
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
VBL Therapeutics, a clinical stage biotechnology company, has announced its financial results for Q3 2022 and provided a corporate update. The company is making progress on evaluating strategic options for its assets, including the GMP manufacturing facility and VB-601 program, with the aim of maximizing shareholder value. It has also filed a regulatory submission for a Phase 1 first-in-human trial for VB-601 and expects to initiate this trial in Q1 2023. To preserve capital, the company has reduced its workforce and ceased internal development of ofra-vec. As of September 30, 2022, VBL had cash and equivalents of $27.7 million.
Management ChangesLayoffs
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
growth-positive
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
Pliant Therapeutics has received a positive safety review from the independent Data Safety Monitoring Board (DSMB) for its ongoing INTGERIS-IPF phase IIa study evaluating PLN-74809 at 320 mg for the treatment of idiopathic pulmonary fibrosis (IPF). The DSMB recommended that the company continue with the study without any modification. The results from the study are expected in early 2023. Following the announcement, the companys stock moved up 5.29% on Sep 1. Pliant Therapeutics shares have returned 50.3% in the year-to-date period.
Investment
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
VBL Therapeutics Announces Second Quarter 2022 Financial Results and Corporate Process to Explore Strategic Options
Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for
VBL Therapeutics Announces Workforce Reduction
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
Read Why VBL Therapeutics Shares Are Falling To a 52-Week Low
growth-negative
VBL Therapeutics Announces Top-Line Data from Phase 3 OVAL Trial of Ofra-Vec in Patients with Platinum-Resistant Ovarian Cancer
VBL Therapeutics announced that its Phase 3 OVAL clinical trial of ofra-vec in platinum-resistant ovarian cancer did not meet the primary endpoints of achieving a statistically significant improvement in progression-free survival or overall survival. The trial results showed no significant difference between the treatment arm and the control arm. As a result, VBL Therapeutics plans to discontinue the OVAL trial and review data from ongoing Phase 2 trials in other cancer types to determine next steps with the ofra-vec program. The company expressed disappointment in the outcome and extended gratitude to trial participants. VBL Therapeutics will continue to move forward with its VB-601 program and expects its current cash on hand to fund operations for at least the next 12 months.
Customers
growth-positive
VBL Therapeutics Enters Into Ordinary Share Purchase Agreement of up to $20 Million With Aspire Capital Fund, LLC
VBL Therapeutics has entered into a Share Purchase Agreement with Aspire Capital Fund, LLC, which allows Aspire to purchase up to $20 million of the companys ordinary shares over a 30-month period. The proceeds from the sales will be used for working capital and general corporate purposes. The agreement provides VBL Therapeutics with access to capital to support their ongoing OVAL phase 3 study of VB-111 in patients with platinum-resistant ovarian cancer. The company also plans to advance the development of VB-601, a first-in-class anti-MOSPD2 monoclonal antibody. The agreement does not contain any restrictions on the use of proceeds or future financings. VBL Therapeutics retains full control over the timing and amount of any share sales to Aspire.
Investment
growth-positive
VBL Therapeutics Announces First Patient in Europe in the OVAL Trial
VBL Therapeutics has expanded its OVAL Phase 3 study of VB-111, a gene therapy product candidate for the treatment of platinum-resistant ovarian cancer, into Europe. The study is actively recruiting patients in the U.S., Israel, and Europe, with over 200 patients enrolled to date. The expansion is expected to accelerate recruitment, diversify the patient population, and support dialogue with European regulatory authorities. VB-111 has shown a significant response rate in previous analyses, and if successful and approved, it has the potential to establish a new standard of care. The study is being conducted in collaboration with the GOG Foundation. VBL Therapeutics is a clinical stage biopharmaceutical company focused on developing treatments for cancer and immune/inflammatory indications.
Customers
growth-positive
VBL Therapeutics Announces Additional New European Patent in the MOSPD2 Platform Technology, This Time for Treatment of Cancer
VBL Therapeutics has been granted a European patent for its investigational anti-MOSPD2 monoclonal antibodies to treat oncology conditions. The patent covers the use of the antibodies to treat a wide range of cancers that express MOSPD2, including solid tumors and hematological cancers. This patent provides intellectual property protection for VBLs MOSPD2 program and its anti-cancer therapy until at least July 2036. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and immune/inflammatory indications.
Investment
growth-positive
Newly Granted European Patent Protects VBL Therapeutics' Anti-MOSPD2 Antibodies for Inflammation Until at least July 2036
VBL Therapeutics has been granted a patent for its investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. The patent provides protection for VBLs MOSPD2 antibodies for inflammation until at least July 2036. The company is currently advancing its lead anti-MOSPD2 candidate through IND-enabling studies and plans to enter the clinic in 2021. VBL recently held a pre-IND meeting with the FDA and has reached alignment with the Agency on the path forward for its lead candidate. A first-in-human study is planned to commence in the second half of 2021.
InvestmentManagement Changes
growth-positive
VBL Presents Human Proof-of-Concept Data That Show the Potential of its Novel anti-MOSPD2 Monoclonal Antibodies for Multiple Sclerosis at the MS Virtual 2020 Meeting
VBL Therapeutics presents new data demonstrating the activity of its investigational anti-MOSPD2 mAbs in patients with multiple sclerosis (MS). The data show that VBLs anti-MOSPD2 mAbs significantly inhibited migration of monocytes in all MS patients included in the study. The company believes that its antibodies offer a novel mechanism for potential treatment of MS by blocking the accumulation of monocytes/macrophages in the central nervous system. VBL is currently advancing its lead anti-MOSPD2 candidate VB-601 through IND-enabling studies. The company aims to start a first-in-human study in the second half of 2021.
Customers
growth-positive
VBL Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Clinical Development of VB-601
VBL Therapeutics has successfully completed a Type B pre-IND meeting with the FDA regarding the development plan for VB-601, the companys lead anti-MOSPD2 antibody for immune-inflammatory indications. The FDAs feedback was positive, and VBL plans to advance its IND-enabling activities for VB-601 as planned. The company aims to start a first-in-human study in the second half of 2021. VB-601 is a proprietary anti-MOSPD2 monoclonal antibody with potential for the treatment of multiple chronic inflammatory diseases. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class cancer treatments.
Partners
growth-positive
VBL Therapeutics to Present Data on New Investigator-Sponsored Phase 2 Trial of VB-111 in Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting
VBL Therapeutics announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented at the 2019 Society for Neuro-Oncology annual meeting. The trial will study VB-111 in rGBM patients undergoing a second surgery and will be conducted at seven top neuro-oncology US centers. The primary endpoint of the study is an immunological readout, and secondary endpoints include progression-free survival and overall survival. The study aims to generate results that can be part of a future filing with regulatory authorities. VBL Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class cancer treatments.
PartnersInvestment
growth-positive
VBL Therapeutics to Provide Additional Details on the New VB-111 Data Presented Earlier This Week at ASCO, in a Presentation at the 2019 BIO International Convention Today
VBL Therapeutics CEO, Dr. Dror Harats, will deliver a company presentation at the 2019 BIO International Convention. The presentation will discuss the recent progress of VB-111, the companys lead oncology product, including data presented at the 2019 ASCO Annual Meeting. VB-111 is a potential first-in-class anticancer therapeutic candidate being studied in a Phase 3 pivotal trial for ovarian cancer. The presentation will be available via webcast.
Partners
VBL Therapeutics reports promising data for anti-cancer gene therapy VB-111
growth-positive
VBL Therapeutics Announces First Patient in Pivotal Phase 3 Study of VB-111 in Platinum Resistant Ovarian Cancer in Collaboration with the GOG Foundation, Inc.
VBL Therapeutics has announced the initiation of its Phase 3 pivotal registration trial, OVAL, for its lead candidate VB-111 in platinum-resistant ovarian cancer. The study will be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation. The OVAL study aims to enroll up to 350 adult patients at clinical sites in the United States and Israel. The primary endpoint is overall survival, with additional endpoints including objective response rate and progression-free survival. VB-111 has shown positive clinical data in previous studies, including a high response rate and better survival in ovarian cancer patients. VBL Therapeutics is also studying VB-111 in a Phase 3 trial for recurrent glioblastoma, with top-line data expected in Q1 2018.
Customers
growth-positive
VBL Therapeutics raising $18.75m in Nasdaq offering
Israeli cancer treatment developer VBL Therapeutics has raised $18.75 million through a public offering on Nasdaq. The funds will be used for the advancement of clinical programs, product development, and general corporate purposes. VBL Therapeutics lead product candidate is a targeted anti-cancer gene-therapy agent for solid tumors, currently being studied in a Phase III pivotal trial for recurrent Glioblastoma.
Investment
growth-positive
VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
VBL Therapeutics announced that the Independent Data Safety Monitoring Committee (DSMC) has recommended that the Phase 3 GLOBE Study investigating ofranergene obadenovec (VB-111) in recurrent glioblastoma (rGBM) continue as planned. The study is comparing VB-111 in combination with Avastin to Avastin alone and has recruited 256 patients in the US, Canada, and Israel. The study is proceeding under a Special Protocol Assessment (SPA) granted by the FDA. The DSMC reviewed the safety data collected through March 2017 and expects the interim analysis to occur in mid-2017, with top-line results available in early 2018.
Investment
growth-positive
Vascular Biogenics raising $22m in Nasdaq offering
Vascular Biogenics, an Israeli drug development and cancer treatment company, is raising $22 million in a secondary offering. The company has agreed to sell approximately 4.36 million ordinary shares to US institutional investors at a purchase price of $5.50 per share. The net proceeds from the offering, estimated to be $22.1 million, will be used for the advancement of clinical programs and other general corporate purposes. Vascular Biogenics recently announced positive Phase I/II results for its ovarian cancer treatment, leading to a significant increase in its share price. The companys market cap is currently $138.56 million.
Investment
growth-positive
VBL Therapeutics' brain cancer drug succeeds in mid-stage study
VBL Therapeutics, an Israel-based company, announced that a mid-stage study of its experimental brain cancer drug, VBL-111, met the main goal of increasing overall survival. The drug, when used in combination with Roche AGs cancer treatment, Avastin, significantly improved overall survival. However, the company stopped testing the drug as a monotherapy after the disease progressed in nearly half the patients in the study who were given only VBL-111. VBL is also testing VBL-111 as a treatment for thyroid cancer and ovarian cancer. The companys shares were up 20 percent following the announcement.
InvestmentExpand
VBL Therapeutics Team
Naama Dym; MSc, MBA
Business Development Associate, IP Manager
Employee Info
| Employees (range) | 11-50 |
| Exact count | 14 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
VBL Therapeutics Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Natalia Golczar |
| Registrar ID | 512899766 |
| Crunchbase | vbl-therapeutics |
| Phone | +97289935000 |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-20T00:00:00.000Z |
| Created | 2014-07-17T00:00:00.000Z |
| Claimed | Yes |
| Status detail | Acquired by Notable Labs on Feb, 2023 |